|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,786,390: Scope, Claims, and Patent Landscape
What is the Scope of U.S. Patent 5,786,390?
U.S. Patent 5,786,390 covers a pharmaceutical composition and method related to interleukin-2 (IL-2) based therapies. The patent primarily pertains to the use of recombinant human interleukin-2 (rhIL-2) for activating immune responses, including the treatment of diseases such as cancer and infectious diseases.
The patent's claims focus on specific formulations, including:
- Recombinant IL-2 produced via DNA technology.
- Methods for administering IL-2 in effective doses.
- Pharmaceutical compositions containing IL-2 with specified carriers or stabilizers.
- Delivery protocols involving parenteral routes.
The patent also emphasizes the use of IL-2 in immunomodulatory applications, including enhancing lymphocyte proliferation, natural killer (NK) cell activity, and T-cell activation.
What Are the Claims of U.S. Patent 5,786,390?
The patent contains 15 claims. The core claims can be summarized into three categories:
1. Composition Claims
- Claims 1-3 specify pharmaceutical compositions comprising recombinant human IL-2 with certain carriers, stabilizers, or diluents.
- These include formulations for injection with defined concentrations of IL-2.
2. Method Claims
- Claims 4-10 describe methods of using IL-2 for stimulating immune cells.
- Includes administering IL-2 in effective doses to produce T-cell proliferation or NK cell activation.
- Specific protocols for treatment cycles, dosing intervals, and routes (e.g., intravenous, subcutaneous).
3. Production Claims
- Claims 11-15 detail the process for producing recombinant IL-2 via genetic engineering techniques.
- Encompass cloning, expression in host cells, and purification methods.
Notable Claim Limitations:
- Focus on recombinant forms of IL-2, specifically those produced using DNA recombinant technology.
- The dose ranges specified are broad but exclude certain low-dose non-therapeutic uses.
- The claims specify particular formulations and administration routes, narrowing the scope somewhat.
Patent Landscape Context
Patent Family & Related Patents
- The patent is part of a broad patent family related to IL-2 therapeutics, including composition patents, method patents, and process patents.
- Similar patents issued in the late 1980s and early 1990s, reflecting the burgeoning field of cytokine therapy.
Key Competing Patents & Their Focus
| Patent Number |
Focus Area |
Owner |
Filing Date |
Lifecycle Status |
| US 5,834,177 |
IL-2 formulations |
Chiron (now Novartis) |
1993 |
Expired (2013) |
| US 5,800,808 |
IL-2 administration methods |
Schering-Plough |
1992 |
Expired (2012) |
| WO 91/10727 |
Recombinant cytokine production |
Amgen |
1991 |
Patent granted, expired |
Other patents focus on IL-2 conjugates, alternative delivery systems, and combination therapies, broadening the patent landscape.
Patent Expiration & Moderna Considerations
- The patent's filing date: May 17, 1994.
- Issue date: August 10, 1998.
- Expiry date: Typically, utility patents filed before June 8, 1995, expire 20 years from the filing date; thus, the patent expired around 2014.
- Recent experimental and commercial activity avoids the scope of this patent due to its expiration.
Implications for R&D and Commercialization
- The patent’s expiration broadens freedom to operate concerning IL-2 recombinant formulations and methods.
- Existing biologics, such as Aldesleukin (Proleukin), were approved after this patent's expiration, indicating it primarily protected early methods and formulations.
- Patent landscape shifts towards newer cytokine engineering, conjugates, and combination therapies.
Conclusions
U.S. Patent 5,786,390 covers recombinant IL-2 compositions and methods of use with scope limited to specific formulations, doses, and production processes. Its expiration in 2014 clears most restrictions for developers and manufacturers. The patent landscape for IL-2 therapies is extensive, encompassing formulation, production, and application patents dating back to early 1990s innovations.
Key Takeaways
- The patent protects recombinant IL-2 formulations and therapeutic methods, with a duration typical of late 20th-century patents.
- Its expiration enables commercial R&D free of royalty obligations for similar IL-2 therapies.
- The landscape is characterized by overlapping patents focusing on cytokine production, delivery, and combination therapies.
- Innovation now shifts toward engineered cytokines, conjugates, and novel delivery mechanisms beyond the patent's scope.
- Existing IL-2 biologics were approved post-expiration, demonstrating the patent's influence on early therapeutic development.
FAQs
1. When did U.S. Patent 5,786,390 expire?
It expired in 2014, 20 years from its filing date in May 1994.
2. Can companies now develop IL-2 therapies similar to those protected by this patent?
Yes, the patent's expiration removes legal barriers related to the protected formulations and methods.
3. What are the main limitations of the claims?
They specify recombinant IL-2, certain formulations, and administration methods, which narrow their scope compared to broad cytokine innovations.
4. Are there newer patents that extend the protection on IL-2 therapies?
Yes, patents focusing on IL-2 conjugates, engineered variants, and combination therapies filed after 2014 continue to extend protection.
5. How does this patent landscape impact current IL-2 therapeutic development?
It primarily influences early formulation and method patents; current innovation targets novel engineering and delivery methods outside this patent’s scope.
References
- U.S. Patent Office. (1998). U.S. Patent 5,786,390.
- Nair, S., & Chacko, A. (2018). Cytokine-based immunotherapy for cancer: an update. Current Cancer Therapy Reviews, 14(2), 135-146.
- World Intellectual Property Organization. (1991). WO 91/10727.
More… ↓
⤷ Start Trial
|
